Y. Salhi

发表

GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis.

G. Gudi, Ning Zhang, G. Wolff, 2019, The Journal of allergy and clinical immunology.

Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination.

W. Rozenbaum, C. Jacomet, V. Schneider, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors.

W. Rozenbaum, A. Giami, Y. Salhi, 2002, Journal of acquired immune deficiency syndromes.

Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.

G. Pond, P. Albers, T. Choueiri, 2013, Clinical genitourinary cancer.

Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.

W. Rozenbaum, C. Vigouroux, J. Capeau, 1999, Diabetes & metabolism.

Randomized, double-blind, placebo-controlled trial of ISC 17536, an oral inhibitor of transient receptor potential ankyrin 1, in patients with painful diabetic peripheral neuropathy: impact of preserved small nerve fiber function

R. Freeman, G. Gudi, R. Baron, 2021, Pain.

Serum ferritin, desferrioxamine, and evolution of HIV-1 infection in thalassemic patients.

P. Rebulla, D. Costagliola, M. D. Montalembert, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Long-term Nonprogression in Hiv Infection

D. Costagliola, Y. Salhi, 1997 .

Efficacy and Safety of Twice-daily and Once-daily Olopatadine-Mometasone Combination Nasal Spray for Seasonal Allergic Rhinitis.

C. Andrews, Y. Salhi, Dale E Mohar, 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.

S. Culine, T. Choueiri, J. Rosenberg, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine

T. Choueiri, J. Rosenberg, J. Bellmunt, 2013, British Journal of Cancer.

Long-term survival results of a randomized phase III trial of vin fl unine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy †

S. Culine, T. Choueiri, J. Bellmunt, 2013 .

Evidence for Activity of GBR830 (Anti‐OX40) in Extrinsic and Intrinsic Atopic Dermatitis (AD) in a Phase 2a Study: 382

G. Wolff, E. Guttman‐Yassky, A. Pavel, 2019, Journal of Allergy and Clinical Immunology.

Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).

W. Rozenbaum, C. Vigouroux, J. Capeau, 1999, Diabetes & metabolism.

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

J. Blay, E. Brain, J. Misset, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.

S. Culine, T. Choueiri, J. Rosenberg, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

S. Culine, J. Carles, J. Bellmunt, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors predictive of disease progression and death in AIDS‐related Kaposi's sarcoma

W. Rozenbaum, D. Costagliola, J. Spano, 2000, HIV medicine.

Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.

R. Ramlau, M. Krzakowski, A. Santoro, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma

G. Pond, P. Albers, T. Choueiri, 2014, BJU international.

Preliminary biomarker and pharmacodynamic data from a phase I study of single-agent bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers.

E. Bayever, M. Wermke, J. Kauh, 2018 .

Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.

Joaquim Bellmunt, T. Choueiri, J. Rosenberg, 2012, European journal of cancer.

Results from a randomized, double-blind, placebo-controlled, exploratory, multicenter study of GBR 830 in adult patients with moderate-to-severe atopic dermatitis

G. Gudi, G. Wolff, Ning Zhang, 2018, Journal of the American Academy of Dermatology.

Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma.

E. Bayever, J. Richter, M. Wermke, 2018 .

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

G. Gudi, C. Huff, M. Mohty, 2022, Blood.

472 Telazorlimab in atopic dermatitis: Phase 2b study shows improvement at 16 weeks

G. Gudi, N. Mozaffarian, Y. Salhi, 2021 .